Rituximab and CHOP Chemotherapy Plus GM-CSF for Previously Untreated Diffuse Large B-Cell Lymphoma in the Elderly: A Wisconsin Oncology Network Study

• Published in: Clinical lymphoma, myeloma and leukemia Vol. 10; no. 5; pp. 379 - 384
• Main Authors: Chang, Julie E, Seo, Songwong, Kim, Kyungmann M, Werndli, Jae E, Bottner, Wayne A, Rodrigues, Gilberto A, Sanchez, Federico A, Saphner, Thomas J, Longo, Walter L, Kahl, Brad S
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2010
• Subjects: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived - administration & dosage; Antibodies, Monoclonal, Murine-Derived - adverse effects; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cyclophosphamide - administration & dosage; Cyclophosphamide - adverse effects; Disease-Free Survival; DLBCL; Doxorubicin - administration & dosage; Doxorubicin - adverse effects; Drug Synergism; Female; Granulocyte-macrophage colony-stimulating factor; Granulocyte-Macrophage Colony-Stimulating Factor - administration & dosage; Granulocyte-Macrophage Colony-Stimulating Factor - adverse effects; Hematology, Oncology and Palliative Medicine; Humans; Lymphoma, Large B-Cell, Diffuse - drug therapy; Male; Middle Aged; Prednisone - administration & dosage; Prednisone - adverse effects; Rituximab; Sargramostim; Toxicity; Treatment Outcome; Vincristine - administration & dosage; Vincristine - adverse effects; DLBCL; Sargramostim; Granulocyte-macrophage colony-stimulating factor; Toxicity

Abstract Purpose Human recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) may potentiate rituximab activity by upregulating CD20 expression and activating effector cells necessary for antibody-dependent cellular cytotoxicity. GM-CSF was combined with standard rituximab + CHOP (cyc...